- Trials with a EudraCT protocol (185)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
185 result(s) found for: Pulmonary vein.
Displaying page 1 of 10.
EudraCT Number: 2017-002340-32 | Sponsor Protocol Number: APIDULCIS | Start Date*: 2019-03-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE ARIANNA ANTICOAGULAZIONE | ||||||||||||||||||
Full Title: APIDULCIS: Extended anticoagulation with low-dose apixaban after a standard course anticoagulation in patients with a first venous thromboembolism who have positive d-dimer | ||||||||||||||||||
Medical condition: a first episode of proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005351-14 | Sponsor Protocol Number: CV185-035 | Start Date*: 2007-05-29 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surg... | ||||||||||||||||||
Medical condition: Subjects undergoing elective total hip replacement (THR) surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) FR (Completed) BE (Completed) GB (Completed) DK (Completed) HU (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004953-27 | Sponsor Protocol Number: CV185-057 | Start Date*: 2008-07-29 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm an... | ||||||||||||||||||
Medical condition: Venous Thromboembolism (VTE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) PT (Completed) GB (Completed) AT (Completed) DK (Completed) CZ (Completed) IT (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016992-31 | Sponsor Protocol Number: COU-001A | Start Date*: 2010-03-19 | |||||||||||||||||||||
Sponsor Name:Democritus Universityof Thrace Medical School [...] | |||||||||||||||||||||||
Full Title: EUropean Pharmacogenetics of AntiCoagulation Therapy trial | |||||||||||||||||||||||
Medical condition: Newly diagnosed patients with venous tromboembolism (VTE) or atrial fibrillation (AF) requiring oral anticoagulation with phenprocoumon. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016993-34 | Sponsor Protocol Number: COU-001W | Start Date*: 2010-09-02 | |||||||||||||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||||||||||||
Full Title: EUropean Pharmacogenetics of AntiCoagulation Therapy trial | |||||||||||||||||||||||
Medical condition: Newly diagnosed patients with venous tromboembolism (VTE) or atrial fibrillation (AF) requiring oral anticoagulation with warfarin. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016994-13 | Sponsor Protocol Number: COU-001P | Start Date*: 2010-03-19 | |||||||||||||||||||||
Sponsor Name:University Utrecht [...] | |||||||||||||||||||||||
Full Title: EUropean Pharmacogenetics of AntiCoagulation Therapy trial | |||||||||||||||||||||||
Medical condition: Newly diagnosed patients with venous tromboembolism (VTE) or atrial fibrillation (AF) requiring oral anticoagulation with phenprocoumon. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) DE (Completed) AT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001786-42 | Sponsor Protocol Number: EFC6034 | Start Date*: 2006-11-08 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfa... | |||||||||||||
Medical condition: Patients with confirmed acute symptomatic pulmonary embolism with or without confirmed acute symptomatic deep vein thrombosis of the lower limbs. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) SK (Completed) SE (Completed) ES (Completed) BE (Completed) AT (Completed) DK (Completed) CZ (Completed) NL (Completed) EE (Completed) GR (Completed) IT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007867-25 | Sponsor Protocol Number: CV185-056 | Start Date*: 2008-08-26 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism. Revised Protocol Number 02 incorporating Amendment(s) 04... | ||||||||||||||||||
Medical condition: Venous Thromboembolism (VTE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) AT (Completed) HU (Completed) ES (Completed) PT (Completed) DK (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000619-26 | Sponsor Protocol Number: BAY59-7939/16416 | Start Date*: 2014-06-11 | ||||||||||||||||||||||||||
Sponsor Name:Bayer HealthCare AG | ||||||||||||||||||||||||||||
Full Title: Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and... | ||||||||||||||||||||||||||||
Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) SE (Completed) AT (Completed) IT (Completed) ES (Completed) GB (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) NL (Completed) NO (Completed) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006896-19 | Sponsor Protocol Number: CV185-047 | Start Date*: 2007-09-06 | |||||||||||||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Tota... | |||||||||||||||||||||||
Medical condition: Venous Thromboembolic Events | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) NL (Completed) AT (Completed) BE (Completed) FR (Completed) HU (Completed) SE (Completed) IT (Completed) CZ (Completed) DK (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005158-73 | Sponsor Protocol Number: SURPRISE-2011 | Start Date*: 2012-04-11 |
Sponsor Name:GWT-TUD GmbH | ||
Full Title: Superficial vein thrombosis (SVT) treated for forty-five days with Rivaroxaban versus Fondaparinux | ||
Medical condition: Lower extremity superficial vein thrombosis (SVT) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001083-43 | Sponsor Protocol Number: BAY 59-7939 / 11223 | Start Date*: 2004-11-23 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis ODIXa-DVT A prospective, randomized, multinational, multicenter, partially blinded, parallel-grou... | |||||||||||||
Medical condition: Acute deep vein thrombosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002171-16 | Sponsor Protocol Number: BAY 59-7939 / 11528 | Start Date*: 2005-01-10 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. | |||||||||||||
Medical condition: Acute syntomatic deep vein thrombosis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003303-31 | Sponsor Protocol Number: BAY59-7939/13238 | Start Date*: 2009-01-13 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: The Einstein CYP cohort study. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism using a strong CYP 3A4 inducer. | ||
Medical condition: Patients with acute, proximal DVT or acute PE who concomitantly use a strong CYP 3A4 inducer for the entire 3-month study duration. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) HU (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-003674-96 | Sponsor Protocol Number: CV185-036 | Start Date*: 2007-07-27 | |||||||||||||||||||||
Sponsor Name:Bristol Myers Squibb | |||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Fo... | |||||||||||||||||||||||
Medical condition: Total Venous thromboembolism (VTE), defined as the combination of fatal or nonfatal pulmonary embolism, symptomatic deep vein thrombosis (DVT), and asymptomatic proximal DVT. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) SE (Completed) NL (Completed) CZ (Completed) AT (Completed) FR (Completed) DK (Completed) HU (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002631-86 | Sponsor Protocol Number: 1160.46 | Start Date*: 2008-10-23 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim Austia Gm.b.H | ||||||||||||||||||
Full Title: A phase III, randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sy... | ||||||||||||||||||
Medical condition: Acute symptomatic VTE VTE is defined as the composite incidence of Deep Vein Thrombosis of the leg (including the inferior caval vein) and Pulmonary Embolism. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) SK (Completed) ES (Completed) GB (Completed) NL (Completed) DK (Completed) CZ (Completed) SE (Completed) HU (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004494-96 | Sponsor Protocol Number: BAY 59-7939/IMP 11899 | Start Date*: 2007-03-19 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary emb... | ||
Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) ES (Completed) SE (Completed) DE (Completed) FI (Completed) FR (Completed) HU (Completed) AT (Completed) IT (Completed) DK (Completed) CZ (Completed) NL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-005184-13 | Sponsor Protocol Number: 50129 | Start Date*: 2017-11-29 |
Sponsor Name:MEDIOLANUM FARMACEUTICI S.P.A. | ||
Full Title: METRO STUDY - MESOGLYCAN VERSUS PLACEBO IN SECONDARY PREVENTION OF SURFACE VEIN THROMBOSIS | ||
Medical condition: patients with SVT of the lower limbs that have completed the acute phase treatment cycle | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001813-17 | Sponsor Protocol Number: R1282 | Start Date*: 2012-08-06 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust | ||||||||||||||||||||||||||||||||||||||
Full Title: Study of apoptosis related changes and endothelial responses of multiple myeloma patients treated with chemotherapy. | ||||||||||||||||||||||||||||||||||||||
Medical condition: Chemotherapy related thrombosis in patients treated for multiple myeloma. | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003492-35 | Sponsor Protocol Number: MED2-201301 | Start Date*: 2015-05-26 |
Sponsor Name:University of Bonn | ||
Full Title: Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran after Pulmonary Vein Isolation for Atrial Fibrillation | ||
Medical condition: atrial fibriallation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
